生命终程的衰弱轨迹:临终衰弱变化与死亡原因
基于英国生物银行37,465例死亡登记数据,用医院衰弱风险评分(HFRS)月度评估死亡前一年衰弱轨迹。神经退行性疾病死者中72.0%呈「晚期稳定衰弱」轨迹,与其他死因者的轨迹分布显著不同;高龄、低教育、慢病负担重与「晚期进展性衰弱」轨迹相关。
要点
- 神经退行性疾病死者以「晚期稳定衰弱」轨迹为主(72.0%),基线衰弱更高。
- 其他死因者以「中期进展性衰弱」为主(46.5%),「持续低衰弱」占24.7%。
- 高龄、低教育、慢病负担重与「晚期进展性衰弱」轨迹相关。
核心结论
- 临终衰弱轨迹因死亡原因而异,神经退行性疾病死者衰弱更严重且以「晚期稳定衰弱」为主。
研究设计与样本
- 基于英国生物银行全国死亡登记链接数据,纳入37,465例死者,用医院衰弱风险评分(HFRS)评估死亡前一年月度衰弱,采用潜类别轨迹模型分析。
主要发现
- 神经退行性疾病死者(2,895例,7.7%)中,快速进展性衰弱占6.9%、中度进展性衰弱占21.1%、晚期稳定衰弱占72.0%。
- 其他死因者中,持续低衰弱占24.7%、中期进展性衰弱占46.5%、晚期进展性衰弱占28.8%。
- 与癌症死者相比,神经退行性疾病死者基线衰弱更高且以「晚期稳定衰弱」轨迹为主。
- 高龄、低教育、更大慢病负担与「晚期进展性衰弱」轨迹相关。
临床怎么用
- 对神经退行性疾病患者应早期识别衰弱,并制定针对性的临终照护策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Frailty changes associated with aging have been well-documented in existing research. However, there is limited evidence on how frailty progresses during the end-of-life stage. We aimed to explore trajectories of frailty in the last year of life and explore how the distribution of these trajectories differs according to the conditions leading to death. METHODS: Based on national death registries linkage data in the UK Biobank, 37,465 decedents were included in the analytic sample. Monthly frailty scores were obtained for 1 year prior to death using the Hospital Frailty Risk Score (HFRS; a cumulative deficit measure of frailty). Latent class trajectory models were used to estimate trajectories of frailty. We further analyzed the distribution of these frailty trajectories across different conditions leading to death. Multinomial logistic regression models were applied to examine the associations between predictors and frailty trajectories. RESULTS: Among 37,465 decedents, 2895 (7.7%) died from neurodegenerative diseases. Three distinct frailty trajectories were identified among these decedents: rapidly progressive frailty (6.9%), moderate progression of frailty (21.1%), and advanced and stable frailty (72.0%). These patterns differed significantly from those observed in decedents with other causes of death, who exhibited persistently low frailty (24.7%), intermediate and progressive frailty (46.5%), and advanced and progressive frailty (28.8%). Compared to cancer decedents, individuals with neurodegenerative diseases had higher baseline frailty and a dominant trajectory of advanced and stable frailty. Older age, lower education, and greater chronic disease burden were associated with the advanced and progressive frailty trajectory. CONCLUSIONS: Frailty trajectories at the end of life varied by cause of death, with neurodegenerative disease decedents exhibiting more severe frailty. These findings underscored the need for early identification of frailty and tailored end-of-life care strategies, particularly for individuals with neurodegenerative diseases who often experienced prolonged and severe frailty.
引用
- Xu J, Mak JK, Xue QL, et al. Mapping the Final Journey: End-Of-Life Frailty Trajectories and Cause of Death. J Am Geriatr Soc. 2025. PMID: 40474749. doi:10.1111/jgs.19567
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。